HBW Advisory Services LLC acquired a new position in iShares Biotechnology ETF (NASDAQ:IBB – Get Rating) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 2,065 shares of the financial services provider’s stock, valued at approximately $271,000.
Several other large investors have also recently made changes to their positions in the stock. Royal Bank of Canada lifted its holdings in shares of iShares Biotechnology ETF by 0.4% in the 3rd quarter. Royal Bank of Canada now owns 1,706,281 shares of the financial services provider’s stock worth $199,568,000 after acquiring an additional 7,013 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in iShares Biotechnology ETF by 49.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,568,159 shares of the financial services provider’s stock worth $204,332,000 after buying an additional 521,820 shares in the last quarter. Jane Street Group LLC lifted its holdings in iShares Biotechnology ETF by 11.2% during the 3rd quarter. Jane Street Group LLC now owns 951,555 shares of the financial services provider’s stock worth $111,294,000 after buying an additional 95,541 shares in the last quarter. Commerce Bank lifted its holdings in iShares Biotechnology ETF by 38.0% during the 3rd quarter. Commerce Bank now owns 689,006 shares of the financial services provider’s stock worth $80,586,000 after buying an additional 189,847 shares in the last quarter. Finally, Barclays PLC lifted its holdings in iShares Biotechnology ETF by 205.0% during the 3rd quarter. Barclays PLC now owns 391,633 shares of the financial services provider’s stock worth $45,806,000 after buying an additional 263,247 shares in the last quarter. 58.02% of the stock is currently owned by institutional investors and hedge funds.
iShares Biotechnology ETF Trading Down 1.8 %
iShares Biotechnology ETF stock opened at $124.50 on Friday. iShares Biotechnology ETF has a 52-week low of $104.29 and a 52-week high of $138.74. The company’s 50 day moving average is $132.12 and its two-hundred day moving average is $128.91.
iShares Biotechnology ETF Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
- Get a free copy of the StockNews.com research report on iShares Biotechnology ETF (IBB)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.